5.73
-1.01(-14.99%)
Currency In USD
| Previous Close | 6.74 |
| Open | 6.49 |
| Day High | 6.49 |
| Day Low | 5.61 |
| 52-Week High | 8.4 |
| 52-Week Low | 3.21 |
| Volume | 13.94M |
| Average Volume | 4.11M |
| Market Cap | 1.39B |
| PE | -24.91 |
| EPS | -0.23 |
| Moving Average 50 Days | 6.69 |
| Moving Average 200 Days | 5.41 |
| Change | -1.01 |
If you invested $1000 in Ardelyx, Inc. (ARDX) 10 years ago, it would be worth $2,106.62 as of February 21, 2026 at a share price of $5.73. Whereas If you bought $1000 worth of Ardelyx, Inc. (ARDX) shares 5 years ago, it would be worth $3,312.14 as of February 21, 2026 at a share price of $5.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class
Ardelyx Receives New Patent for Tenapanor
GlobeNewswire Inc.
Feb 03, 2026 1:29 PM GMT
New patent covers IBSRELA® and XPHOZAH® and expires in 2042WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-i
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
GlobeNewswire Inc.
Jan 28, 2026 1:29 PM GMT
WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs